Patrick Simpson, MD
Interventional Cardiology · Pinehurst, NCNPI 1841234887
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $483,071 of the $579,344 with a category attached, or 83.4%. 60 manufacturers reported payments, led by Boehringer Ingelheim at 30.0% of the total. Reporting peaked in 2019 at $175,046 and has fallen 71.1% since, to $50,667 in 2025. Among interventional cardiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,119 payments — averaging $517.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$174K
- Lilly USA, LLC$160K
- Novartis$60K
- Boston Scientific$51K
- AstraZeneca$48K
- Sanofi-aventis U.S. LLC$37K
- plus $49K from 54 others
Across 106 payments — averaging $10,068 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$601K
- American Regent$301K
- Kowa Research Institute, Inc.$79K
- AstraZeneca$44K
- Amgen$35K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- plus $431 from 1 others
What the payments were for
- Consulting fees$11,7802%
- Speaking & faculty fees$483,07183%
- Travel & lodging$57,23910%
- Food & beverage$27,2025%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$306,753
- ENTRESTO$59,276
- PRALUENT$46,059
- WATCHMAN Access System$43,245
- BRILINTA$30,921
- NEXLIZET$23,360
- NEXLETOL$23,360
- FARXIGA$16,175
- TRULICITY$12,150
- WATCHMAN FLX$4,463
- VERQUVO$3,023
- RYBELSUS$1,275
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$935
- Impella$624
- AMPLATZER Occluders$454
- AVVIGO Guidance System$274
- FLOWTRIEVER CATHETER, S$234
- CT THROMBECTOMY SYSTEM KIT$234
- Repatha$229
- TELEMARK MICROCATHETER$200
How this compares
$579,344 in reported general payments places this provider in the 95th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 115 | $115,853 |
| EliquisApixaban | 138 | $115,392 |
| EntrestoSacubitril/Valsartan | 81 | $74,893 |
| JardianceEmpagliflozin | 67 | $54,067 |
| BrilintaTicagrelor | 57 | $31,256 |
| MultaqDronedarone Hcl | 33 | $28,102 |
| FarxigaDapagliflozin Propanediol | 28 | $24,155 |
| Repatha SureclickEvolocumab | 17 | $10,180 |
| Praluent PenAlirocumab | 12 | $5,906 |
| Ranolazine ErRanolazine | 43 | $2,859 |
| SotalolSotalol Hcl | 93 | $1,616 |
| Valsartan | 19 | $1,326 |
| ClopidogrelClopidogrel Bisulfate | 134 | $1,166 |
| Carvedilol | 179 | $1,085 |
| Rosuvastatin Calcium | 103 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $481 | $115,853115 claims |
| PfizerEliquis | $480 | $115,392138 claims |
| NovartisEntresto | $59,598 | $74,89381 claims |
| AstraZenecaBrilinta, Farxiga | $48,334 | $55,41185 claims |
| Boehringer IngelheimJardiance | $173,968 | $54,06767 claims |
| Sanofi-aventis U.S. LLCMultaq | $36,586 | $28,10233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Pinehurst
- Steven FilbyPinehurst$442K
- William HarrisPinehurst$15K
- Peter DuffyPinehurst$12K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Naveed RajperStatesville$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.